These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1767729)

  • 21. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults.
    Yuen K; Frystyk J; Umpleby M; Fryklund L; Dunger D
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3956-64. PubMed ID: 15292333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects.
    Rasmussen MH; Hvidberg A; Juul A; Main KM; Gotfredsen A; Skakkebaek NE; Hilsted J; Skakkebae NE
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1407-15. PubMed ID: 7536210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.
    Hussain MA; Schmitz O; Mengel A; Glatz Y; Christiansen JS; Zapf J; Froesch ER
    J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans.
    Hartman ML; Clayton PE; Johnson ML; Celniker A; Perlman AJ; Alberti KG; Thorner MO
    J Clin Invest; 1993 Jun; 91(6):2453-62. PubMed ID: 8514857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men.
    Corpas E; Harman SM; Piñeyro MA; Roberson R; Blackman MR
    J Clin Endocrinol Metab; 1993 Jan; 76(1):134-8. PubMed ID: 8421077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of recombinant human IGF-I on glucose and leucine kinetics in men.
    Elahi D; McAloon-Dyke M; Fukagawa NK; Sclater AL; Wong GA; Shannon RP; Minaker KL; Miles JM; Rubenstein AH; Vandepol CJ
    Am J Physiol; 1993 Dec; 265(6 Pt 1):E831-8. PubMed ID: 8279537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect?
    Kovacs GT; Worgall S; Schwalbach P; Steichele T; Mehls O; Rosivall L
    Horm Res; 1999; 51(4):193-200. PubMed ID: 10474022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats.
    Grøfte T; Wolthers T; Jensen SA; Møller N; Jørgensen JO; Tygstrup N; Orskov H; Vilstrup H
    Hepatology; 1997 Apr; 25(4):964-9. PubMed ID: 9096605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin-like growth factor-I and growth hormone have different effects on serum lipoproteins and secretion of lipoproteins from cultured rat hepatocytes.
    Sjöberg A; Oscarsson J; Olofsson SO; Edén S
    Endocrinology; 1994 Oct; 135(4):1415-21. PubMed ID: 7925103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
    Hanew K; Tanaka A
    J Endocrinol Invest; 2001 Jan; 24(1):1-7. PubMed ID: 11227726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. rhIGF-I administration in humans: differential metabolic effects of bolus vs. continuous subcutaneous delivery.
    Mauras N; Martha PM; Quarmby V; Haymond MW
    Am J Physiol; 1997 Apr; 272(4 Pt 1):E628-33. PubMed ID: 9142884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.
    Kupfer SR; Underwood LE; Baxter RC; Clemmons DR
    J Clin Invest; 1993 Feb; 91(2):391-6. PubMed ID: 7679407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effects of central and peripheral administration of growth hormone (GH) and insulin-like growth factor on hypothalamic GH-releasing hormone and somatostatin gene expression in GH-deficient dwarf rats.
    Sato M; Frohman LA
    Endocrinology; 1993 Aug; 133(2):793-9. PubMed ID: 8102097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic and splanchnic metabolic response to exogenous human growth hormone.
    Dahn MS; Lange MP
    Surgery; 1998 May; 123(5):528-38. PubMed ID: 9591005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation.
    Hokken-Koelega AC; Hackeng WH; Stijnen T; Wit JM; de Muinck Keizer-Schrama SM; Drop SL
    J Clin Endocrinol Metab; 1990 Sep; 71(3):688-95. PubMed ID: 2394775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.
    Laager R; Ninnis R; Keller U
    J Clin Invest; 1993 Oct; 92(4):1903-9. PubMed ID: 8408642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.